1 ml of the solution contains:

• active substance – naphazoline nitrate - 1 mg;
• excipients - boric acid, purified water.

Nasal spray 0.1%, 10 ml

Nasal preparations. Anticongestants and other nasal medications for topical use. Sympathomimetics. Naphazoline.

ATC code R01AA08

• acute rhinitis;
• inflammation of the nasal sinuses;
• to reduce swelling during diagnostic and therapeutic procedures.

• hypersensitivity to the components of the product;
• dry inflammation of the nasal mucosa;
• children under 15 years of age;
• hyperthyroidism;
• chronic rhinitis;
• diabetes mellitus;
• dry rhinitis;
• arterial hypertension;
• coronary heart disease;
• pheochromocytoma;
• tachycardia;
• severe eye diseases;
• pronounced atherosclerosis;
• closed angle glaucoma;
• concomitant use of MAO inhibitors and up to 14 days after the end of their use.

Nasal spray 0.1% is used in adults and children over 15 years of age by 1 injection into each nasal passage 2-3 times a day, but not more often than 4 hours.

Apply for no more than 7 days. Take a break for a few days before using again.

Burning sensation and dryness in the nasal cavity, reactive hyperemia; with prolonged use - nasal mucous membrane swelling; allergic reactions, very rare - Quincke's edema.

If used for more than 1 week, it can be addictive.

Prolonged use may cause atrophic rhinitis.

Too frequent use can lead to dependence accompanied by intense mucosal edema occurring within a relatively short time after application. Prolonged use of the product may lead to disruption of the mucosal epithelium, inhibition of ciliary activity and lead to irreversible mucosal damage and development of dry rhinitis.

Overdose or accidental ingestion of the product may manifest as symptoms of systemic effects of the product: increased blood pressure, tachycardia, headache, tremor, irritability, increased sweating, palpitations, impaired consciousness. Cyanosis, nausea, cardiac arrest, pulmonary edema, mental disorders, increase in body temperature may occur. The depressing effect on the central nervous system is manifested by the following symptoms: drowsiness, bradycardia, decreased body temperature, shock, apnea, coma.

In case of an accidental overdose, stop using the product and consult a doctor immediately.

Use of the product during pregnancy and lactation is possible only if the expected benefits to the mother exceed the risk to the fetus and the baby.

Approved for children over 15 years of age.

Prolonged use of the product can lead to chronic nasal congestion and mucosal atrophy.

With prolonged use the vasoconstrictor effect gradually decreases (tachyphylaxis phenomenon), therefore it is recommended to use the product for not more than 5 days.

The product should be used very carefully in people with severe cardiovascular disease, with bronchial asthma. Caution should be exercised during general anesthesia with anesthetics that increase myocardial sensitivity to sympathomimetics (e.g., halothane) in patients with bronchial asthma.

Prolonged use and overdose should be avoided. Prolonged use of medicines designed to relieve mucosal edema can lead to swelling and subsequent atrophy of the nasal mucosa.

10 ml of the product in polypropylene bottles with a spray lid and a protective cap. One bottle is with instruction for use in the state and Russian language are placed in a carton pack.

Store in a place protected from light at a temperature of 18°С to 25°С.

Keep out of the reach of children.

3 years

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan, tel.: (727) 253-03-88.

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan.

Name, address, contact information of the organization accepting claims (proposals) against quality of products from consumers in the territory of the Republic of Kazakhstan, which is responsible for post-authorization safety surveillance of the medicine:

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan,

Tel./Fax: (727) 253-07-07, 253-03-88, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.